pharmaphorum1d
Why the drug pricing debate is focused on insulin
would ultimately lower the cost of all products on the market. One company that received approval for an insulin biosimilar in the US is Viatris, for its Semglee (insulin glargine-yfgn ...
Capital Public Radio2d
Newsom committed California to making its own insulin. It’s at least a year behind his schedule
With copay caps however, the long-term costs are still passed down ... but there is no timeline for when the first insulin — a generic for glargine — will be available on the market.
centerforbiosimilars1d
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...
pharmaphorum5d
Civica plans shake-up of insulin sector with low-cost biosimilars
The average wholesale prices of the originator insulin are around $329 per vial ... FDA approval for a biosimilar product version of Lantus – Semglee – that is completely interchangeable ...
Kiplinger1y
GoodRx Is Offering $35 Insulin Coupons — And You Don't Need Insurance
Telehealth platform GoodRx has become the latest company to offer people with diabetes access to insulin for $35 per month— regardless of whether they have insurance. GoodRx said in a statement ...
Medscape3y
Dose-response Effects of Insulin Glargine in Type 2 Diabetes
Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and ...